Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABVIMGF 82 3-Year EBITDA Growth Rate is 27.90% as of Jun. 2026, which is 5% above its 10-year median of 26.45. GuruFocus rates VIMGF with a GF Score™ of 82/100 and a GF Value™ of $2.78. The stock has 4 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 69.7% on this metric.
During the past 12 months, Vimian Group AB's average EBITDA Per Share Growth Rate was 33.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -24.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vimian Group AB was 166.00% per year. The lowest was -59.80% per year. And the median was 26.45% per year.
Vimian Group AB (OTCPK:VIMGF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vimian Group AB 3-Year EBITDA Growth Rate Related Terms
VIMGF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's 3-Year EBITDA Growth Rate falls into.
Vimian Group AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.90% mean?
Vimian Group AB (VIMGF) has a 3-Year EBITDA Growth Rate of 27.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vimian Group AB and its competitors. This is near median its historical median of 26.45. According to the industry distribution chart, Vimian Group AB ranks #50 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 30.3%.
Is Vimian Group AB's 3-Year EBITDA Growth Rate too high?
Vimian Group AB's current 3-Year EBITDA Growth Rate of 27.90% is near median its 10-year median of 26.45. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.50. Vimian Group AB's value of 27.90% is 142.6% above this industry median. Based on the distribution chart, Vimian Group AB ranks #50 out of 165 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #50 out of 165 companies for 3-Year EBITDA Growth Rate. This puts Vimian Group AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.50. Vimian Group AB's value of 27.90% is 142.6% above this benchmark. While the company's 10-year median is 26.45 vs. the industry median of 11.50, Vimian Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.50, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current 3-Year EBITDA Growth Rate of 27.90% is 142.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current 3-Year EBITDA Growth Rate is 27.90%, which is near median its own 10-year median of 26.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current 3-Year EBITDA Growth Rate of 27.90%. The stock's GF Value™ is $2.78, compared to a current price of $2.77 — trading 0.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 27.90%, which is near median its 10-year median of 26.45 and 142.6% above the Medical Diagnostics & Research industry median of 11.50. Vimian Group AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current 3-Year EBITDA Growth Rate is 27.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 0.4% below its estimated GF Value™ of $2.78.
Key valuation signals for VIMGF:
3-Year EBITDA Growth Rate: 27.90% (near median its 10-year median of 26.45)
GF Value™: $2.78 vs. price of $2.77 (0.4% below fair value)
Industry Position: 142.6% above the Medical Diagnostics & Research median (#50 of 165)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
82GF Score
Get the complete analysis for VIMGF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
